Jefferson Health in Philadelphia is suing Aetna over a new Medicare Advantage payment policy that hospitals say unfairly ...
Value-based care and Medicare Advantage are often heralded as two of healthcare’s most promising strategies for controlling costs, but industry leaders can’t quite tell if they’re actually working.
Generic medicines face no tariffs, though the Trump administration reserves the right to revisit that in the future. Some ...
Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...
Every year, thousands of Americans end up in emergency rooms for issues that could have been treated — and often prevented — in a dentist’s office. From a small cavity that goes unnoticed to severe ...
GLP-1 drugs currently available for weight loss are administered as once-weekly injections. Verdiva Bio also aims to bring to patients once-a-week dosing, but in a more convenient pill. That would ...
Monday night at HIMSS is an evening for fun, thanks to the many corporate-sponsored parties. HIStalkapalooza, run by the HIStalk blog, a.k.a. the National Enquirer of Health IT, has grown by leaps and ...
Intermountain Health, the largest nonprofit healthcare provider in the Intermountain West region, struck a multi-year collaboration with a young generative AI startup this month. The health system is ...
Corewell Health is demonstrating just how important it is to address the root causes of chronic disease. The Michigan-based health system released data this month showing that its partnership with ...
Concurrent review is a utilization review process that occurs while a patient is actively receiving treatment, such as during a hospital stay. It evaluates the medical necessity and appropriateness of ...
Millions of Americans are struggling to access physical and behavioral healthcare, and providers across the country are overworked, understaffed and face significant economic pressure. Nonetheless, ...